Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.

Phase 3

Completed

Conditions: Haemophilia B
Congenital Bleeding Disorder

Interventions: Drug: nonacog beta pegol

First Posted Date: 2011-11-08

Last Posted Date: 2024-04-02

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 25

Registration Number: NCT01467427

Locations: 🇺🇸
Maimonides Medical Center, Brooklyn, New York, United States
🇺🇸
Mount Sinai Medical Center, New York, New York, United States
🇺🇸
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States

and more 23 locations

A Trial Investigating the Effect of NN1250 in Japanese Subjects With Type 2 Diabetes

Phase 1

Terminated

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: insulin degludec

First Posted Date: 2011-11-08

Last Posted Date: 2013-11-27

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1

Registration Number: NCT01467414

Safety and Efficacy of Insulin Aspart in Children With Type 1 Diabetes

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin aspart
Drug: human insulin
Drug: isophane human insulin

First Posted Date: 2011-11-08

Last Posted Date: 2017-02-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 26

Registration Number: NCT01467141

Locations: 🇩🇪
Novo Nordisk Investigational Site, Osnabrück, Germany

Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: biphasic insulin aspart
Drug: biphasic human insulin

First Posted Date: 2011-11-08

Last Posted Date: 2017-01-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 303

Registration Number: NCT01467323

Locations: 🇬🇧
Novo Nordisk Investigational Site, Whiston, United Kingdom

Efficacy and Safety of NovoMix® 30 in Subjects With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2
Diabetes

Interventions: Drug: biphasic insulin aspart
Drug: biphasic human insulin

First Posted Date: 2011-11-08

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 292

Registration Number: NCT01467401

Locations: 🇸🇪
Novo Nordisk Investigational Site, Östersund, Sweden

Long Term Safety and Efficacy of Biphasic Insulin Aspart 30 in Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: biphasic insulin aspart

First Posted Date: 2011-11-08

Last Posted Date: 2017-02-24

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 89

Registration Number: NCT01467375

Locations: 🇨🇦
Novo Nordisk Investigational Site, Saskatoon, Canada

Comparison of Metformin, Repaglinide or the Combination of Both in Subjects With Type 2 Diabetes

Phase 4

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 2

Interventions: Drug: metformin
Drug: repaglinide

First Posted Date: 2011-11-04

Last Posted Date: 2017-02-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 182

Registration Number: NCT01465152

Locations: 🇪🇸
Novo Nordisk Investigational Site, Zaragoza, Spain

Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin aspart

First Posted Date: 2011-11-03

Last Posted Date: 2016-10-28

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 24

Registration Number: NCT01464099

Locations: 🇺🇸
Novo Nordisk Investigational Site, Chula Vista, California, United States

A Trial to Test for Bioequivalence Between NN1045 and NN5401 in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes

Interventions: Drug: insulin degludec/insulin aspart

First Posted Date: 2011-10-19

Last Posted Date: 2015-02-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 32

Registration Number: NCT01455142

Evaluating Safety of NovoPen® 3 and/or FlexPen® Devices in Routine Clinical Practice

Completed

Conditions: Delivery Systems
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 1
Diabetes

Interventions: Device: FlexPen®
Device: NovoPen® 3

First Posted Date: 2011-10-18

Last Posted Date: 2015-06-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1031

Registration Number: NCT01454024

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy